Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics (NASDAQ: KDNY) announced participation in key virtual investor conferences scheduled for January 2021. Notable events include the H.C. Wainwright Bioconnect 2021 Conference on January 11 and the 39th Annual J.P. Morgan Healthcare Conference on January 12. Additionally, 1x1 meetings will occur from January 11 to January 14. Interested investors can access live webcasts and archived recordings through Chinook's website for 30 days. The company focuses on precision medicines for kidney diseases, including its lead program, atrasentan, for IgA nephropathy.

VANCOUVER, British Columbia and SEATTLE, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in presentations at the following upcoming virtual investor conferences:

• H.C. Wainwright Bioconnect 2021 Conference – fireside chat will be available on-demand beginning Monday, January 11^th at 6:00 am EST
  
  
• 39^th Annual J.P. Morgan Healthcare Conference – Tuesday, January 12^th at 2:50 pm EST
  

Chinook will also participate in 1x1 meetings through J.P. Morgan on Monday, January 11^th – Thursday, January 14^th.

To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 30 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
510-809-2465
investors@chinooktx.com
media@chinooktx.com

FAQ

When is Chinook Therapeutics participating in the H.C. Wainwright Bioconnect 2021 Conference?

Chinook Therapeutics will participate in the H.C. Wainwright Bioconnect 2021 Conference on January 11, 2021.

What time is the J.P. Morgan Healthcare Conference presentation by Chinook?

Chinook Therapeutics is scheduled to present at the J.P. Morgan Healthcare Conference on January 12, 2021, at 2:50 pm EST.

How can investors access Chinook's conference presentations?

Investors can access live webcasts and archived recordings of Chinook's presentations on the company's website.

What is the focus of Chinook Therapeutics as a company?

Chinook Therapeutics specializes in developing precision medicines for kidney diseases.

What is the lead program of Chinook Therapeutics?

Chinook's lead program is atrasentan, an investigational treatment for IgA nephropathy.